| Personalized oncology solutions | 511K |
| Translational oncology solutions | 3.16M |
| Total operating revenue | 3.67M |
| Cost of personalized oncology solutions | 474K |
| Cost of translational oncology solutions | 2.05M |
| Research and development | 1.21M |
| Sales and marketing | 925K |
| General and administrative | 1.53M |
| Total costs and operating expenses | 6.19M |
| Loss from operations | -2.52M |
| Change in fair value of warrant liability | |
| Other income | |
| Total other income | -9K |
| Loss before provision for income taxes | -2.53M |
| Provision for income taxes | 14K |
| Net loss | -2.55M |
| Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share) | -0.26 |
| Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares) | |